• Technology
    • First Access Challenge
    • Resources
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Blog
  • Contact
Nautilus Biotechnology
  • Technology
    • First Access Challenge
    • Resources
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial Information
    • IR Resources
  • Blog
  • Contact

Proteomics and the development of precision medicines against cancer (Part 1)

January 24, 2023
Tyler Ford
LinkedInTwitter

Cancer is a heterogenous mixture of diseases characterized by, among other things, the abnormal, uncontrolled growth of cells derived from otherwise healthy tissues (Hanahan 2022). Although cancer cells sometimes grow into balls of cells and stop there (so-called benign tumors), often they gain the ability to disperse throughout the body, seed the growth of other tumors, disrupt the function of a variety of organs, and ultimately kill patients. In this series of blog posts, we discuss how proteomics can drive the creation and use of “precision medicines” that target the processes enabling cancer growth and stop cancer in its tracks. 

 

Want to read the full series now? Download the “Proteomics and the development or precision medicines against cancer” white paper here.

 

Targeting cancer with precision medicines 

Cancer cells generally acquire the initial ability to multiply beyond their normal boundaries through mutations in genes that control cell growth. Such initial mutations set cells on a path to expand and divide rapidly, gain more mutations, attract blood vessels, and travel to other tissues (Hanahan and Weinberg 2011). 

  

Recognizing the origin of cancer in such “driver” mutations, scientists have made many efforts to develop cancer treatments that target the proteins encoded in these mutated genes. Unfortunately, these efforts have only been successful for cancers with very strong driver mutations. For instance, a fusion of 2 genes can cause chronic myeloid leukemia (CML). The encoded fusion protein continuously signals for immune stem cells to grow and divide thereby leading to leukemia (Rumpold and Webersinke 2011). By targeting this protein with chemical (“small molecule”) drugs, so-called “precision medicines,” cancer growth is disrupted and most patients go into remission for years (Hochhaus et al 2017).

 

Image highlighting how "driver" mutations can lead to cancer development. Driver mutations cause healthy cells to transform into cancer cells that grow and multiply beyond their normal, healthy boundaries. Although a single mutation may be responsible for cancer development, there will likely be many other mutations that are inconsequential and it is hard to tell the difference between such mutations using genomic sequencing data alone. As cancer progresses, cancer cells acquire more mutations that enable them to continue to grow and spread throughout the body. Once again, the mutations that drive this process come with inconsequential mutations.

Figure 1. Driver mutations and cancer progression.
Driver mutations (red) cause healthy cells (blue) to transform into cancer cells (yellow) that grow and multiply beyond their normal, healthy boundaries. Although a single mutation (red) may be responsible for cancer development, there will likely be many other mutations (pink) that are inconsequential and it is hard to tell the difference between such mutations using genomic sequencing data alone. As cancer progresses, cancer cells acquire more mutations that enable them to continue to grow and spread throughout the body. Once again, the mutations that drive this process (red) come with inconsequential mutations (pink).

 

The need for proteome-powered precision medicines

Deciphering the means through which this fusion protein causes CML was by no means easy and it took decades to develop drugs against it. Nonetheless, many cancer-associated mutations cause disease in much less straightforward ways and are harder to develop precision medicines against. For example, cancer cells often have mutations comprising large inversions, duplications, deletions, insertions, or even translocations of long stretches of the 23 human chromosomes. One such translocation causes the gene fusion described above, but these chromosomal abnormalities can impact many genes at once and it is rarely obvious which of encoded proteins should be targeted with a drug. 

  

Other times, there are many small changes to genes throughout a cancer cell’s genome. Many of these mutations will not have any impact on the encoded proteins and looking at DNA sequences alone is only the starting point for a scientist trying to understand their functional consequences. 

  

Even if a scientist can identify a driver mutation in a specific gene, the encoded protein might not be easy to target with a therapeutic. For instance, scientists may not have chemical compounds that can bind to and affect the function of the mutated protein in any significant way. Thus, they may wish to look at the downstream impacts of this mutation to find proteins that are altered indirectly. These may be easier to target. For example, if a driver mutation in a protein known as a transcription factor causes it to enhance the production of growth-promoting proteins, scientists might want to target these growth-promoting proteins instead of the transcription factor. In this case, knowing the driver mutation alone would be insufficient for scientists to know what growth-promoting proteins to target. They would need to know how the production of other proteins changed as a result of the driver mutation. Proteins with increased abundance in cells containing the driver mutations might make good drug targets. 

 

Overall, sequencing the DNA of cancer cells can give scientists clues as to the cause of a cancer and, in rare cases, may give them a precise protein to target therapeutically. However, in many cases, knowing information only about the static genome is neither enough to diagnose the particular type of cancer nor guide the best treatments. 

  

Proteomics can complement DNA sequencing (genomics) and give researchers much more information about the mix of proteins found in cancer cells. Indeed, a cell’s “proteome” is its precise protein make-up including protein abundances, protein modifications, and protein distribution throughout the cell. Advanced proteomics technologies, like those being developed at Nautilus, aim to rapidly catalog the proteomes of cells grown in the lab or derived from patients. In the next two posts in this series, we discuss how advanced proteomics technologies can have far reaching impacts on cancer and can improve therapeutic outcomes. 

 

Want to read the full series now? Download the “Proteomics and the development or precision medicines against cancer” white paper here. 

Browse by topic

  • Nautilus in the News
  • Events
  • Research and collaborations
  • Nautilus and our Platform
  • Proteomics
  • Life at Nautilus
  • Industry Interviews
SUBSCRIBE
Back To Blog

Nautilus Biotechnology

 

Corporate Headquarters
2701 Eastlake Avenue East
Seattle, WA 98102

 

Research Headquarters
835 Industrial Road, Suite 200
San Carlos, CA 94070

 

     

+1 (206) 333-2001

© 2022 Nautilus Biotechnology Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

We use cookies in order to continually improve your experience on our website. By clicking “Accept cookies” or clicking on any content on our site, you are consenting to our use of cookies as described in our Privacy Policy. You can opt-out if you wish. Accept Reject All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT